Bill Sibold, new Madrigal Pharmaceuticals CEO

NASH com­pa­ny Madri­gal names for­mer Sanofi ex­ec Bill Si­bold as new CEO

Madri­gal Phar­ma­ceu­ti­cals has ap­point­ed ex-Sanofi ex­ec­u­tive Bill Si­bold as its new CEO, suc­ceed­ing Paul Fried­man, who will con­tin­ue to serve on the biotech’s board of di­rec­tors.

Si­bold was pre­vi­ous­ly ex­ec­u­tive vice pres­i­dent of spe­cial­ty care at Sanofi, where he over­saw 10,000 peo­ple work­ing across five spe­cial­ty ther­a­peu­tic ar­eas. Un­der his lead­er­ship, the spe­cial­ty care unit sus­tained dou­ble-dig­it growth and launched its block­buster an­ti-in­flam­ma­to­ry der­ma­tol­ogy prod­uct Dupix­ent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.